Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.60 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.57 |
| ▸ | PNP | P00491 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181375 | 0.88 | TK1 (0.56) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL8493219 | 0.82 | TK1 (0.64) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL10436398 | 0.82 | TK1 (0.67) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL29286376 | 0.81 | TK1 (0.76) | TK1HPRT1PNPBLM | |
| SCHEMBL711244 | 0.81 | TK1 (0.69) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL7262060 | 0.80 | HPRT1 (0.61) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL7262066 | 0.80 | HPRT1 (0.61) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL7268685 | 0.80 | HPRT1 (0.61) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL7173165 | 0.80 | TK1 (0.68) | TK1HPRT1PNPMEN1ALDH1A1 | |
| SCHEMBL13524526 | 0.80 | TK1 (0.60) | TK1HPRT1PNPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-02-05 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| US-6576763-B1 | Stereospecific acylation; viricides for herpes and retroviruses | MEDIVIR AB (SE) | 2003-06-10 | — | — | US | disclosed |
| EP-0880521-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| EP-0888348-B1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020188125-A1 | Acyclic nucleoside derivatives | MEDIVIR AB | 2002-12-12 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-6255312-B1 | VIRICIDES | MEDIVIR AB (SE) | 2001-07-03 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | TK1 96/4885HPRT1 37/4885PNP 14/4885 |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | TK1 95/4885HPRT1 19/4885PNP 2/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | TK1 172/4885HPRT1 113/4885PNP 130/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | TK1 96/4885HPRT1 37/4885PNP 14/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | TK1 104/4885HPRT1 16/4885PNP 2/4885 |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | TK1 129/4885HPRT1 33/4885PNP 8/4885 |
| US-20020188125-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | TK1 78/4885HPRT1 20/4885PNP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.